Literature DB >> 19254482

Immunotherapeutical potential of Mycobacterium vaccae on M. tuberculosis infection in mice.

Li Jun Xu1, Yan Yan Wang, Xiao Dong Zheng, Xiang Dong Gui, Li Feng Tao, Hai Ming Wei.   

Abstract

Tuberculosis remains the worldwide infectious disease. To identify the therapeutic potential of M. vaccae in treating tuberculosis, M. vaccae was injected into Mycobacterium tuberculosis (M. tuberculosis) infected mice. The optimal dose of M. vaccae (22.5 microg/mouse) treated mice showed lower pathological change index, spleen weight index, lung weight index and vital M. tuberculosis count than those of the untreated group. Treatment with M. vaccae enhanced the percentages of CD3+ and CD4+ T cells, IFN-gamma+CD4+ T cells, innate immune cells including NK cells, NK1.1+ T cells and gammadeltaT cells, and reduced the percentage of IL-4+CD4+ T cells. Therefore, M. vaccae could protect the mice from M. tuberculosis infection and improve mouse innate and adaptive cell-mediated immunity, suggesting that M. vaccae is a potential immunotherapeutic agent in pulmonary tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254482      PMCID: PMC4002552          DOI: 10.1038/cmi.2009.9

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  7 in total

Review 1.  Vaccines versus immunotherapy: overview of approaches in deciding between options.

Authors:  Angus G Dalgleish
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Syntheses and biological evaluation of new cephalosporin-oxazolidinone conjugates.

Authors:  Shanshan Yan; Marvin J Miller; Timothy A Wencewicz; Ute Möollmann
Journal:  Medchemcomm       Date:  2010-05-05       Impact factor: 3.597

Review 3.  Current and novel approaches to vaccine development against tuberculosis.

Authors:  Mark J Cayabyab; Lilia Macovei; Antonio Campos-Neto
Journal:  Front Cell Infect Microbiol       Date:  2012-12-06       Impact factor: 5.293

4.  Mycobacterium vaccae induces a strong Th1 response that subsequently declines in C57BL/6 mice.

Authors:  Lijiao Zhang; Yanlong Jiang; Ziyin Cui; Wentao Yang; Limin Yue; Yingcong Ma; Shaohua Shi; Chunfang Wang; Chunfeng Wang; Aidong Qian
Journal:  J Vet Sci       Date:  2016-12-30       Impact factor: 1.672

5.  Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes.

Authors:  Wen-Ping Gong; Yan Liang; Yan-Bo Ling; Jun-Xian Zhang; You-Rong Yang; Lan Wang; Jie Wang; Ying-Chang Shi; Xue-Qiong Wu
Journal:  Mil Med Res       Date:  2020-06-03

6.  Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung.

Authors:  Ankan Gupta; Farhan J Ahmad; Faiz Ahmad; Umesh D Gupta; Mohan Natarajan; Vishwamohan Katoch; Sangeeta Bhaskar
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

7.  Mycobacterial Response to Organic Solvents and Possible Implications on Cross-Resistance With Antimicrobial Agents.

Authors:  Cátia Pacífico; Pedro Fernandes; Carla C C R de Carvalho
Journal:  Front Microbiol       Date:  2018-05-15       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.